4587 Stock Overview
A biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
PeptiDream Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥2,215.00 |
| 52 Week High | JP¥2,929.00 |
| 52 Week Low | JP¥1,039.00 |
| Beta | 0 |
| 11 Month Change | -19.45% |
| 3 Month Change | 14.38% |
| 1 Year Change | 21.97% |
| 33 Year Change | -42.84% |
| 5 Year Change | -59.73% |
| Change since IPO | 208.17% |
Recent News & Updates
Recent updates
PeptiDream Inc. Just Beat Revenue Estimates By 13%
Aug 12
PeptiDream Inc. (TSE:4587) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Jun 30News Flash: Analysts Just Made A Meaningful Upgrade To Their PeptiDream Inc. (TSE:4587) Forecasts
Jun 02PeptiDream Inc.'s (TSE:4587) 42% Price Boost Is Out Of Tune With Revenues
Apr 30Is PeptiDream Inc. (TSE:4587) Trading At A 46% Discount?
Apr 29PeptiDream Inc.'s (TSE:4587) 25% Jump Shows Its Popularity With Investors
Mar 03Shareholder Returns
| 4587 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 3.6% | 4.2% | 3.2% |
| 1Y | 22.0% | -0.2% | 15.0% |
Return vs Industry: 4587 exceeded the JP Biotechs industry which returned -0.2% over the past year.
Return vs Market: 4587 exceeded the JP Market which returned 15% over the past year.
Price Volatility
| 4587 volatility | |
|---|---|
| 4587 Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 12.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in JP Market | 10.0% |
| 10% least volatile stocks in JP Market | 3.4% |
Stable Share Price: 4587's share price has been volatile over the past 3 months.
Volatility Over Time: 4587's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 603 | Patrick Crawford Reid | www.peptidream.com |
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates -based therapeutics and diagnostics. Its development pipeline include PD-L1 indicated for oncology and currently under Ph1 clinical phase development stage; PD-L1 BMS-986229 indicated for oncology and currently under Ph1 clinical phase development stage; CD38 BHV-1100 + NK Cells indicated for multiple myeloma and currently under Ph1 clinical phase development stage; S2-protein PA-001 indicated for COVID-19 and currently under Ph1 clinical phase development stage; GhR AZP-3813 indicated for acromegaly/NET and currently under Ph1 clinical phase development stage; Glypican-3 indicated for liver cancer and currently under preclinical development stage; Myostatin indicated for DMD/muscle disorders and currently under preclinical development stage; TfR indicated for neuromuscular disorders and currently under preclinical development stage; c-Kit indicated for allergic condition and currently under preclinical development stage; c-Met currently under preclinical development stage; and HA-protein indicated for influenza and currently under preclinical development stage.
PeptiDream Inc. Fundamentals Summary
| 4587 fundamental statistics | |
|---|---|
| Market cap | JP¥289.62b |
| Earnings (TTM) | JP¥21.69b |
| Revenue (TTM) | JP¥55.42b |
13.2x
P/E Ratio5.2x
P/S RatioIs 4587 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4587 income statement (TTM) | |
|---|---|
| Revenue | JP¥55.42b |
| Cost of Revenue | JP¥12.20b |
| Gross Profit | JP¥43.22b |
| Other Expenses | JP¥21.53b |
| Earnings | JP¥21.69b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 167.34 |
| Gross Margin | 77.98% |
| Net Profit Margin | 39.14% |
| Debt/Equity Ratio | 35.6% |
How did 4587 perform over the long term?
See historical performance and comparison